Table 4.
Univariate analysis of survival by explicative variables.
| Overall Survival | Local Control | Distant Metastasis Free Survival | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Classifications | HR | 95% CI | p-Value | HR | 95% CI | p-Value | HR | 95% CI | p-Value |
| Age, years | >70 vs. <70 | 1.78 | 0.7–4.5 | 0.22 | 0.55 | 0.05–5.4 | 0.61 | 0.86 | 0.3–2.4 | 0.77 |
| Histologies | Endometrial vs. cervix vs. ovary |
0.58 | 0.3–1 | 0.18 | 1.43 | 0.4–4.4 | 0.48 | 0.74 | 0.4–1.3 | 0.52 |
| N of mets | ≥2 vs. <2 | 3.32 | 1–10 | 0.020 | 5.4 | 0.5–57.1 | 0.12 | 5.57 | 1.7–18 | 0.001 |
| Systemic therapy | Neoadjuvant vs. concurrent/adjuvant | 0.46 | 0.1–1.3 | 0.13 | 1 | 0.09–10.5 | 0.98 | 0.73 | 0.2–2 | 0.53 |
| Time primary-RT (months) | <30 vs. ≥30 | 3.09 | 1–8.8 | 0.024 | 0.19 | 0–80 | 0.08 | 2.48 | 0.8–6.8 | 0.066 |
| BED10 (Gy) | <70 vs. ≥70 | 1.98 | 0.7–5.3 | 0.16 | 1.71 | 0.2–12.4 | 0.58 | 0.96 | 0.3–2.6 | 0.94 |
| <60 vs. ≥60 | 1.3 | 0.4–3.6 | 0.59 | 0.68 | 0.07–6.6 | 0.74 | 0.98 | 0.3–2.7 | 0.97 | |
| EQD2 (Gy) | <60 vs. ≥60 | 2.5 | 0.9–6.9 | 0.050 | 1.7 | 0.2–12.4 | 0.58 | 1.34 | 0.5–3.5 | 0.55 |
| GTV (cc) | ≥10 vs. <10 | 2.95 | 1.1–8 | 0.022 | 0.3 | 0.04–1.97 | 0.35 | 3.03 | 0.9–9.3 | 0.037 |
| Dm GTV (mm) | ≥20 vs. <20 | 2.93 | 1–7.9 | 0.024 | 0.44 | 0.04–4.3 | 0.47 | 2.71 | 0.9–7.6 | 0.045 |
| PTV (cc) | ≥15 vs. <15 | 1.65 | 0.6–4 | 0.23 | 0.41 | 0.04–4.3 | 0.48 | 1.61 | 0.6–4.1 | 0.28 |
BED: biologically effective dose; Dm: diameter; EQD2: equivalent 2Gy dose; GTV: gross tumor volume; HR: hazard ratio; mets: metastasis; N: number; PTV: planning target volume; RT: radiotherapy.